Female Reproductive System Neuroendocrine Carcinoma

Female Reproductive System Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Novartis Pharmaceuticals
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07006727	Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors	recruiting	Phase 1	116	Novartis PharmaceuticalsINDUSTRY	4	Sep 22, 2026	clinicaltrials
NCT04723095	Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR)	recruiting	—	750	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026